Whereas CAR-T–associated CRS is typically driven by rapid T-cell proliferation and high levels of interleukin-6 and interferon-gamma [8, 25], chemotherapy-induced antigen release may act as an amplifier, precipitating delayed CRS. This evidence concerns the gene IL6 and congenital rubella syndrome.